XNAS · Healthcare · Biotechnology
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | 0.43 | 2.22 | +416.28% | $98.0M | ✅ Beat | -0.62% | +2.75% | — |
| 2026-02-25 | Q4 2025 | 0.39 | 1.94 | +397.44% | $114.6M | ✅ Beat | +4.13% | -6.23% | -6.52% |
| 2025-11-05 |
| Q3 2025 |
| 0.42 |
| 1.08 |
| +157.14% |
| $107.8M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | 0.49 | 0.77 | +57.14% | $100.3M | ✅ Beat | +4.11% | +12.93% | +12.22% |
| 2025-05-07 | Q1 2025 | 0.38 | -0.74 | -294.74% | $88.6M | ❌ Miss | -0.85% | -3.90% | +15.15% |
| 2025-02-26 | Q4 2024 | 0.37 | 0.26 | -29.73% | $91.8M | ❌ Miss | — | — | — |
| 2024-11-06 | Q3 2024 | 0.26 | 0.02 | -92.31% | $89.5M | ❌ Miss | — | — | — |
| 2024-07-31 | Q2 2024 | 0.23 | -0.55 | -339.13% | $99.9M | ❌ Miss | — | — | — |
Showing last 8 quarters.